On September 15th, 2021, the Food and Drug Administration (FDA) approved Exkivity (mobocertinib) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in EGFR called exon 20 insertion. The FDA based their approval on the results [...]
By Jennifer C. King, PhD, Chief Scientific Officer, GO2 for Lung Cancer Surgery has been the primary treatment for early stage non-small cell lung cancer (NSCLC). Unfortunately, many people have seen their cancer come back after surgery. Now researchers [...]
By Andrew Ciupek, PhD, Senior Manager, Clinical Research, GO2 for Lung CancerA number of studies presented at the American Society of Clinical Oncology’s (ASCO) Annual Meeting related to the treatment of non-small cell lung cancer (NSCLC) with an EGFR mutation.Tagrisso [...]
By Rashmi Acharya, MS, Coordinator, Science & Research, GO2 for Lung CancerChemotherapy has been the standard treatment option for Non-Small Cell Lung Cancer (NSCLC) without actionable biomarkers. Recently, immunotherapy treatments have been added into the treatment mix. Several studies presented [...]
A lung cancer diagnosis can feel overwhelming, even confusing. And while every diagnosis is different, one thing is the same: if you or someone you love is faced with lung cancer, we’re here to help. GO2 for Lung Cancer [...]
Amanda Nerstad, SPACEWALK participant, with family By Daniel A. Saez, MSc, Treatment and Trials Navigator, GO2 for Lung Cancer One of the biggest concerns within the mutation positive non-small cell lung cancer (NSCLC) community is the concept [...]
By Rashmi Acharya, MS; Andrew Ciupek, PhD; Jennifer C. King, PhD; and Daniel Saez, MSc The annual meeting held by the American Society of Clinical Oncology (ASCO) is the stage for presenting many of the most impactful advancements in cancer research – including in lung cancer. Health equity was the major theme of the 2021 meeting, held June 4-8, 2021, and multiple [...]
On May 28, 2021 the United States Food and Drug Administration (FDA) approved Lumakras (sotorasib) for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having the G12C change in KRAS. The FDA based their approval [...]
On May 21st, 2021, the Food and Drug Administration (FDA) approved Rybrevant (amivantamab-vmjw) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in EGFR called exon 20 insertion. The FDA based their approval on the results of [...]
Author: Carl M. Gay, MD, PhD of MD Anderson Cancer Center Dr. Carl Gay received our 2018 Young Investigator Award. He graciously agreed to write this summary of new research, including his own, that is poised to make a [...]